Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Desmopressin vs Epinephrine in DCR
NCT05507476Completed
- Sponsor
- Zagazig University
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of desmopressin in nasolacrimal duct obstruction (NLDO) (2 arms), sponsored by Zagazig University. Primary endpoint: Intraoperative blood loss at 60 minutes. Started Sep 2022; status: completed.
02
Drugs
desmopressin
03
Conditions
nasolacrimal duct obstruction (NLDO)
Beyond the preview
Go deeper on NCT05507476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507476.